This situation is comparable to the first option discussed above, with the difference that, in case no subsequent medical uses are claimed, the initial product patent on a first medical use will comprise all possible subsequent uses, rather than being use-bound. Such modest contributions to the existing state of the art are referred to as “incremental innovation”. Such innovation often lies within the range local firms, particularly those that could not realistically aspire to developing truly new or non-obvious inventions that may require more technical research capabilities than are available.